<DOC>
	<DOC>NCT00905047</DOC>
	<brief_summary>The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.</brief_summary>
	<brief_title>Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Further study details as provided by Centre Oscar Lambret.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Locally advanced or metastatic colorectal cancer Age &gt; or = 18 years old PSWHO &lt; or = 2 Polynuclear neutrophil leukocytes &gt; or = 1500/mm3, platelets &gt; or = 100000/mm3 Total bilirubin &lt; or = 3 ULN, ASATALAT &lt; or = 2.5 ULN Effective contraception Written informed consent signed Concomitant radiotherapy Contraindication to fluoropyrimidines Treatment with sorivudine and its chemical analogs such as brivudine Severe hepatic insufficiency Severe renal insufficiency Pregnant or lactating woman Hypersensitivity to capecitabine, 5FU, tegafur or one of its excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>colo-rectal cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced or metastatic colo-rectal cancer</keyword>
</DOC>